➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Moodys
McKesson
Express Scripts
Harvard Business School

Last Updated: January 23, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Ergonovine

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Ergonovine?

Ergonovine is an investigational drug.

There have been 10 clinical trials for Ergonovine. The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2018.

The most common disease conditions in clinical trials are Hemorrhage, Postpartum Hemorrhage, and Uterine Inertia. The leading clinical trial sponsors are Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Turin, Italy, and Johns Hopkins University.

There are four hundred and eighty-three US patents protecting this investigational drug and three international patents.

Recent Clinical Trials for Ergonovine
TitleSponsorPhase
Multimodal Uterotonics at the Time of Cesarean Section in Laboring PatientsNicole M. MassePhase 4
Effect of Amlodipine Versus Amlodipine Combined With Atorvastatin on the Coronary Vasospastic AnginaKosin University Gospel HospitalPhase 4
Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical TrialBrigham and Women's HospitalPhase 4

See all Ergonovine clinical trials

Clinical Trial Summary for Ergonovine

Top disease conditions for Ergonovine
Top clinical trial sponsors for Ergonovine

See all Ergonovine clinical trials

US Patents for Ergonovine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ergonovine   Start Trial Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof Gel-Del Technologies, Inc. (St. Paul, MN)   Start Trial
Ergonovine   Start Trial Methods and systems for the delivery of a therapeutic agent UNIVERSITY OF ICELAND (Reykjavik, IS)   Start Trial
Ergonovine   Start Trial Pyrimidines as sodium channel blockers Purdue Pharma L.P. (Stamford, CT)   Start Trial
Ergonovine   Start Trial Treatment of sexual dysfunction Rejoy (Irvine, CA)   Start Trial
Ergonovine   Start Trial Compositions and methods for prophylaxis and treatment of addictions Omeros Corporation (Seattle, WA)   Start Trial
Ergonovine   Start Trial Crystallization method and bioavailability GRUNENTHAL GMBH (DE)   Start Trial
Ergonovine   Start Trial Substituted piperidin-4-amino-type compounds and uses thereof Purdue Pharma L.P. (Stamford, CT)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ergonovine

Drugname Country Document Number Estimated Expiration Related US Patent
Ergonovine World Intellectual Property Organization (WIPO) WO2010057177 2028-11-17   Start Trial
Ergonovine Argentina AR088029 2031-09-02   Start Trial
Ergonovine Australia AU2012300567 2031-09-02   Start Trial
Ergonovine Canada CA2846463 2031-09-02   Start Trial
Ergonovine Cyprus CY1119327 2031-09-02   Start Trial
Ergonovine Denmark DK2753606 2031-09-02   Start Trial
Ergonovine European Patent Office EP2753606 2031-09-02   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Moodys
McKesson
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.